Showing results (91-100 of 142) with videos related to
Sort By:
Pageof 15
AIDS (London, England)|October 24, 2013
A systematic review of definitions of extreme phenotypes of HIV control and progressionDeepti Gurdasani, Louise Iles, David G Dillon, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 24, 2011
Uptake of combination antiretroviral therapy and HIV disease progression according to geographical origin in seroconverters in Europe, Canada, and AustraliaInma Jarrin, Nikos Pantazis, M John Gill, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|November 1, 2007
Changes in outcome of persons initiating highly active antiretroviral therapy at a CD4 count less than 50 Cells/mm3Kholoud Porter, Sarah Walker, Teresa Hill, et al.BMC Medicine|January 9, 2019
HIV-1 molecular transmission clusters in nine European countries and Canada: association with demographic and clinical factorsDimitrios Paraskevis, Apostolos Beloukas, Kostantinos Stasinos, et al.BMC Medicine|June 24, 2016
Beyond viral suppression of HIV - the new quality of life frontierJeffrey V Lazarus, Kelly Safreed-Harmon, Simon E Barton, et al.Journal of Hepatology|April 17, 2017
Lack of decline in hepatitis C virus incidence among HIV-positive men who have sex with men during 1990-2014Daniela Katinka van Santen, Jannie Johanna van der Helm, Julia Del Amo, et al.AIDS (London, England)|October 17, 2018
Effect of incident hepatitis C infection on CD4+ cell count and HIV RNA trajectories based on a multinational HIV seroconversion cohortDaniela K van Santen, Jannie J van der Helm, Giota Touloumi, et al.AIDS (London, England)|October 17, 2018
Virological remission after antiretroviral therapy interruption in female African HIV seroconvertersMorgane Gossez, Genevieve Elizabeth Martin, Matthew Pace, et al.AIDS (London, England)|December 6, 2005
The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapyDeenan Pillay, Krishnan Bhaskaran, Suzanne Jurriaans, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|June 26, 2009
Is 1 alanine transaminase >200 IU enough to define an alanine transaminase flare in HIV-infected populations? A new definition derived from a large cohort studyLoveleen Bansi, Jo Turner, Richard Gilson, et al.Pageof 15